Australia's Immutep extends gain on FDA orphan drug status for cancer drug

Immutep

16/04/2026 03:24

** Shares of Australian biotechnology firm Immutep IMM.AX rise as much as 22.2% to A$0.075, their highest since March 6

** Stock extends gain from the previous session when it closed 84.6% higher after receiving U.S. FDA Orphan Drug Designation for Eftilagimod Alfa to treat a type of cancer

** About 154.1 mln shares change hands, 3.1x the 30-day average of 50.2 mln

** Stock down 81.3% YTD, including current moves

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))